-+ 0.00%
-+ 0.00%
-+ 0.00%

Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $12

Benzinga·05/19/2026 12:50:43
Listen to the news
Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and lowers the price target from $35 to $12.